CAS 1374248-81-3

Formula: C29H23F6N5O3

InChI: InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1

InChI key: QIVUCLWGARAQIO-OLIXTKCUSA-N

SMILES: C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F

Atogepant

CAS: 1374248-81-3

Atogepant

Formula: C₂₉H₂₃F₆N₅O₃

Purity: ≥98%

Molecular weight: 603.52

Ref: 54-BUP03384

Atogepant

CAS: 1374248-81-3

Formula: C₂₉H₂₃F₆N₅O₃

Molecular weight: 603.53

Ref: 4Z-A-389001

Atogepant-d4

CAS: 1374248-81-3

Formula: C₂₉H₁₉D₄F₆N₅O₃

Molecular weight: 607.55

Ref: 4Z-A-389011

(3′S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxamide

CAS: 1374248-81-3

Formula: C₂₉H₂₃F₆N₅O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 603.5150

Ref: IN-DA01EGMU

Atogepant

CAS: 1374248-81-3

(S)-N-((3S,5S,6R)-6-Methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide

Formula: C₂₉H₂₃F₆N₅O₃

Purity: 98%

Molecular weight: 603.52

Ref: IN-DG01481456

Atogepant-d4 (Spiro Ring-d4)

CAS: 1374248-81-3

Formula: C₂₉H₁₉D₄F₆N₅O₃

Molecular weight: 607.55

Ref: 4Z-A-389002

Atogepant

CAS: 1374248-81-3

Formula: C₂₉H₂₃F₆N₅O₃

Molecular weight: 603.53

Ref: ST-EA-CP-A219000

Atogepant

CAS: 1374248-81-3

Atogepant (MK-8031) is an orally available, selective and potent calcitonin gene-related peptide receptor (CGRP) antagonist for the study of migraine.

Formula: C₂₉H₂₃F₆N₅O₃

Purity: 99.77% - 99.78%

Color and Shape: Solid

Molecular weight: 603.515

Ref: TM-T26682

Atogepant

CAS: 1374248-81-3

Formula: C₂₉H₂₃F₆N₅O₃

Molecular weight: 603.5

Ref: BE-RMCA313000

Atogepant

CAS: 1374248-81-3

Atogepant is a drug for the treatment of migraine that belongs to the group of anti-migraine drugs. It has been shown to inhibit the synthesis of cholesterol, which may be one of its mechanisms for prevention of migraines. Atogepant also inhibits microbial infections through inhibition of growth and can be used as a prophylactic agent against bacterial and viral infections. Atogepant is not active against fungi or parasites. The drug has been observed to have few side effects in women, and it does not affect liver function. It is thought that atogepant binds to a receptor on trigeminal nerve cells, which leads to activation of these cells and subsequent relief from migraine pain.

Formula: C₂₉H₂₃F₆N₅O₃

Purity: Min. 95%

Molecular weight: 603.52 g/mol

Ref: 3D-FA165700